RNS Number : 6517F
Beximco Pharmaceuticals Ltd
08 November 2022
 

8 November 2022

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

BEXIMCO PHARMACEUTICALS LIMITED.

 

Results for the twelve-month period ended 30 June 2022

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its audited results for the twelve months ended 30 June 2022.

 

Highlights

 

Financial (consolidated) - Strong domestic performance underpins growth in challenging macro environment

 

·      Net sales increased 17.5% to Bangladesh Taka ("BDT") 34,669.2m / £309.7m (2020-21: BDT 29,493.6m / £251.4m)

Domestic sales increased 21.3% to BDT 31,984.1m/ £285.8m (2020-21: BDT 26,369.6m / £224.8m)

Export sales decreased 14.0% to BDT 2,685.1m / £24.0m (2020-21: BDT 3,124.0m / £26.6m)

·      Profit after tax decreased 3.2% to BDT 4,998.6m / £44.7m (2020-21: BDT 5,165.7m / £44.0m)

·      EPS for the year amounted to BDT 11.48

·      Recommended 35% cash dividend (BDT 3.5 per share)

 

Operational - continued strengthening of domestic position while building international presence

 

·      Launched a total of 30 new products (fifty-one presentations) in Bangladesh market, nine of them introduced for the first time in the country

·      Launched world's first generic of MSD's Molnupiravir, an oral antiviral drug for COVID-19 treatment as well the first generic copy of Pfizer's Paxlovid, the first US FDA approved breakthrough drug for COVID-19 treatment

·      Completed acquisition of 54.6% stake in Sanofi Bangladesh Limited with effect from 1 October 2021; and subsequently changed the name of the company to Synovia Pharma PLC; integration on-track

·      Launched three new products (seven presentations) from subsidiary, Synovia Pharma PLC, in the domestic market including the antihistamine product Phenergan Plus first time in Bangladesh

·      Distributed 8 million doses of Oxford/AstraZeneca COVID-19 vaccine over the period, with a cumulative 15 million doses delivered under the tripartite agreement between the Serum Institute of India (SII), Government of Bangladesh (GOB) and Beximco Pharma

Looking forward, the broader availability of Covid-19 vaccines in Bangladesh (due, in part, to donations made directly to Bangladesh), means that it is unlikely that GOB will seek to procure any further vaccine doses through this agreement for the foreseeable future

·      Granted two sub-licences by the United Nations-backed Medicines Patent Pool (MPP) to produce the generic versions of MSD's Molnupiravir and Pfizer's Paxlovid (both COVID-19 drugs)

·      Won the Global Generics & Biosimilars Awards 2021 in the category of "Company of the year, Asia Pacific"

·      Won Global Generics & Biosimilars Awards 2022 in the category of Acquisition of the year, (post-period)

 

US

·      Received US FDA approval for Baclofen tablets (muscle relaxant) and Minocycline tablets (tetracycline antibiotic)

·      Received US FDA approval for Eletriptan tablets and Oxybutynin tablets (post-period)

UK

·      Started manufacturing of Olopatadine Eye Drop, indicated for the treatment of allergic conjunctivitis, under CMO arrangement with a UK Company

·      Received Marketing Authorizations for Beta-Cardone (Sotalol) tablets and Quinine Bisulphate tablets in the UK. Beta-Cardon is prescribed to treat fast irregular heartbeats and Quinine Bisulphate is used in the treatment of chloroquine-resistant malaria and for the nocturnal leg cramps in adults and the elderly.

RoW

·      Completed 32 registrations for 28 products in 11 countries

·      Entered four new countries: Morocco, St.Lucia, Georgia, Timor-Leste (East Timor)

·      Received approval for Bromhexine tablets in Australia (post-period)

 

Update on COVID-19 Vaccine Supply

As noted above, there was an increase in COVID-19 vaccine supply into Bangladesh in the second half of the financial year, including substantial donations of surplus vaccine from other countries. This, combined with a widespread lack of desire for a third dose from the general population, means that it is unlikely that any further orders will be made through the agreement between SII, GOB and Beximco Pharma and that little to no revenues will be associated with this deal for the foreseeable future. A further announcement will be made in the event that this status changes.

 

Beximco Pharma managing director Nazmul Hassan MP commented,

 

"In the current challenging macro environment, we are delighted to be able to report another period of revenue growth. While we have seen the economic downturn have an adverse impact on some of our export markets, this has been more than offset by our domestic performance. With organic growth coupled with the acquisition of Sanofi Bangladesh (now Synovia Pharma), we have continued to further consolidate our domestic market position. Simultaneously, we have maintained our focus on growing our position in high-value markets, such as the US and UK through more product approvals during the period.  

 

"Over the first quarter of the new financial year, we are seeing the impact of numerous headwinds such as the war in Ukraine, supply chain disruptions and record depreciation of local currency. While we expect these issues to have an impact on Q1 and beyond, we remain committed to expanding our businesses, seeking operational efficiencies and delivering on our strategy to maximise the potential of Beximco Pharma."

 

 

Exchange rates of £1 = Taka 117.32 for 2020-21 numbers and £1 = Taka 111.93 for 2021-22 numbers have been used in this announcement.

 

 

 

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 586/11001, Ext.20080

 

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext.20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, ext.20030

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Vadim Alexandre / Abigail Wayne

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

 

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.



 

 

 

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated Statement of Financial Position As at June 30, 2022

 




Amount in Taka


June 30, 2022

 

June 30, 2021

ASSETS




Non-Current Assets

47,728,777,460

 

38,475,237,847

Property, Plant and Equipment- Carrying Value

41,760,330,727


36,211,375,594

Right-of-use Assets

618,891,376


319,884,849

Intangible Assets

4,562,988,045


1,380,693,809

Deferred Tax Asset

88,640,228


-

Goodwill

674,570,185


546,691,213

Other Investments

23,356,899


16,592,382

Current Assets

 

18,419,258,282

 

 

13,770,846,179

Inventories

10,405,295,079


7,142,863,477

Spares & Supplies

718,797,256


661,722,724

Accounts Receivable

3,142,817,194


2,873,844,874

Loans, Advances and Deposits

2,787,039,904


2,416,948,496

Advance Income Tax

196,635,028


-

Cash and Cash Equivalents

1,168,673,821


675,466,608

TOTAL ASSETS

66,148,035,742

 

52,246,084,026

 




EQUITY AND LIABILITIES




Equity Attributable to the Owners of the Company

40,600,497,817

 

37,030,558,202

Issued Share Capital

4,461,120,890


4,461,120,890

Share Premium

5,269,474,690


5,269,474,690

Excess of Issue Price over Face Value of GDRs

1,689,636,958


1,689,636,958

Capital Reserve on Merger

294,950,950


294,950,950

Revaluation Surplus

1,116,896,688


1,121,824,646

Unrealized Gain/(Loss)

20,531,723


13,767,206

Retained Earnings

27,747,885,918


24,179,782,862

Non-Controlling Interest

 

4,035,506,641

 

 

334,306,627

TOTAL EQUITY

44,636,004,458

 

37,364,864,829

Non-Current Liabilities

8,776,099,208

 

5,531,540,789

Long Term Borrowings-Net of Current Maturity

3,454,188,843


1,206,717,094

Liability for Gratuity, Pension and WPPF & Welfare Funds

2,785,072,661


2,335,257,766

Deferred Tax Liability

2,536,837,704


1,989,565,929

 

Current Liabilities and Provisions

 

12,735,932,076

 

 

9,349,678,408

Short Term Borrowings

6,850,550,319


5,023,181,128

Long Term Borrowings-Current Maturity

2,065,962,471


1,401,406,013

Creditors and Other Payables

2,465,039,217


1,965,048,180

Accrued Expenses

1,166,881,586


619,399,363

Dividend Payable / Unclaimed Dividend

88,049,428


118,137,390

Income Tax Payable

99,449,055


222,506,334

TOTAL EQUITY AND LIABILITIES

66,148,035,742

 

52,246,084,026



 

 

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated Statement of Profit or Loss and Other Comprehensive Income For the Year ended June 30, 2022

 

 

 


Amount in Taka

 

July 2021- June 2022

 

July 2020 - June 2021

 

 

 

 

Net Revenue

34,669,172,052

 

29,493,573,869

Cost of Goods Sold

(18,854,919,733)


(15,570,071,581)

Gross Profit

15,814,252,319

 

13,923,502,288

 

 

 

 

Operating Expenses

(8,912,966,372)

 

(7,272,794,940)

Administrative Expenses

(1,163,406,037)


(896,648,965)

Selling, Marketing and Distribution Expenses

(7,749,560,335)


(6,376,145,975)

Profit from Operations

6,901,285,947

 

6,650,707,348

Other Income

1,146,717,162


908,275,284

Finance Cost

(1,001,835,523)


(858,685,146)

Profit Before Contribution to WPPF & Welfare Funds

7,046,167,586

 

6,700,297,486

Contribution to WPPF & Welfare Funds

(359,222,585)


(322,749,293)

Income Tax Expenses

(1,688,316,804)

 

(1,211,798,461)

Current Tax

(1,191,180,488)


(1,386,678,310)

Profit After Tax

4,998,628,197

 

5,165,749,732

Profit/(Loss) Attributable to:




Owners of the Company

5,123,136,712


5,127,693,711

Non-Controlling Interest

(124,508,515)


38,056,021


4,998,628,197

 

5,165,749,732

6,764,517


12,840,831

5,005,392,714

 

5,178,590,563

 

 

 

Owners of the Company

5,129,901,229


5,140,534,542

Non-Controlling Interest

(124,508,515)


38,056,021


5,005,392,714

 

5,178,590,563

 

Earnings Per Share (EPS)

 

11.48

 

 

11.49

 



 

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated Statement of Changes in Equity

For the Year Ended June 30, 2022

 

 

As at June 30, 2022

Amount in Taka


Share Capital

Share

Premium

Excess of Issue Price over Face Value of GDRs

Capital Reserve on Merger

Revaluation Surplus

Unrealized Gain/ (Loss)

Retained Earnings

Equity attributable to Owners of the Company

Non- Controlling Interests

Total Equity

Balance as on July 01, 2021

4,461,120,890

5,269,474,690

1,689,636,958

294,950,950

1,121,824,646

13,767,206

24,179,782,862

37,030,558,202

334,306,627

37,364,864,829

NCI at the date of acquisition-SPP

-

-

-

-

-

-

-

-

3,857,134,718

3,857,134,718

Total Comprehensive Income:


Profit for the Year

-

-

-

-

-

-

5,123,136,712

5,123,136,712

(124,508,515)

4,998,628,197

Other Comprehensive Income/(Loss)

-

-

-

-

-

6,764,517

-

6,764,517

-

6,764,517

Transactions with the Shareholders:

Cash Dividend

-

-

-

-

-

-

(1,561,392,312)

(1,561,392,312)

(31,426,189)

(1,592,818,501)

Adjustment for Depreciation on Revalued Assets

-

-

-

-

(6,358,656)

-

6,358,656

-

-

-

Adjustment for Deferred Tax on Revalued Assets

-

-

-

-

1,430,698

-

-

1,430,698

-

1,430,698

Balance as on June 30, 2022

4,461,120,890

5,269,474,690

1,689,636,958

294,950,950

1,116,896,688

20,531,723

27,747,885,918

40,600,497,817

4,035,506,641

44,636,004,458

 

Net Asset Value (NAV) Per Share

 

 

 

 

 

 

Tk.

 

91.01

 


 

 

 

As at June 30, 2021

Amount in Taka

 

Share Capital

Share Premium

Excess of Issue Price over Face Value of GDRs

Capital Reserve on Merger

Revaluation Surplus

Unrealized Gain/ (Loss)

Retained Earnings

Equity attributable to Owners of the Company

Non- Controlling Interests

Total Equity

Balance as on July 01, 2020

4,055,564,450

5,269,474,690

1,689,636,958

294,950,950

1,125,767,451

926,375

20,058,799,733

32,495,120,607

302,329,006

32,797,449,613

Total Comprehensive Income:


Profit for the Year

-

-

-

-

-

-

5,127,693,711

5,127,693,711

38,056,021

5,165,749,732

Other Comprehensive Income/(Loss)

-

-

-

-

-

12,840,831

-

12,840,831

-

12,840,831

Transactions with the Shareholders:

Cash Dividend

-

-

-

-

-

-

(608,334,668)

(608,334,668)

(6,078,400)

(614,413,068)

Stock Dividend

405,556,440

-

-

-

-

-

(405,556,440)

-

-

-

Adjustment for Depreciation on Revalued Assets

-

-

-

-

(7,180,526)

-

7,180,526

-

-

-

Adjustment for Deferred Tax on Revalued Assets

-

-

-

-

3,237,721

-

-

3,237,721

-

3,237,721

Balance as on June 30, 2021

4,461,120,890

5,269,474,690

1,689,636,958

294,950,950

1,121,824,646

13,767,206

24,179,782,862

37,030,558,202

334,306,627

37,364,864,829

 

Net Asset Value (NAV) Per Share

 

 

 

 

 

 

 

Tk.

 

 

83.01

 

 

 



 

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated Statement of Cash Flows

For the Year ended June 30, 2022

 

 

 

 

Amount in Taka

 

July 2021- June 2022

 

July 2020- June 2021

Cash Flows from Operating Activities:




Receipts from Customers and Others

36,125,979,245


30,833,168,257

Payments to Suppliers and Employees

(28,565,273,290)


(22,500,770,314)

Cash Generated from Operations

7,560,705,955

 

8,332,397,943

Interest Paid

(1,002,350,838)


(861,452,888)

Interest Received

3,055,358


2,377,286

Income Tax Paid

(1,347,234,025)


(1,450,058,386)

Net Cash Generated from Operating Activities

5,214,176,450

 

6,023,263,955

Cash Flows from Investing Activities :




Acquisition of Property, Plant and Equipment

(2,931,097,076)


(2,520,682,923)

Intangible Assets

(8,400,918)


(37,734,793)

Investment in Subsidiary

(4,766,635,704)


-

Disposal of Property, Plant and Equipment

24,063,832


32,831,171

Dividend Received

2,015,444


940,700

Net Cash Used in Investing Activities

(7,680,054,422)

 

(2,524,645,845)

Cash Flows from Financing Activities :




Net Increase /(Decrease) in Long Term Borrowings

2,730,647,211


(504,636,764)

Net Increase/(Decrease) in Short Term Borrowings

1,507,676,748


(2,375,180,232)

Dividend Paid

(1,623,098,759)


(578,351,025)

Net Cash (Used in) / from Financing Activities

2,615,225,200

 

(3,458,168,021)

Increase/(Decrease) in Cash and Cash Equivalents

149,347,228

 

40,450,089

Cash and Cash Equivalents at Beginning of Year*

973,963,625


635,016,519

Effect of Exchange Rate Changes on Cash and Cash Equivalents

45,362,968


-

Cash and Cash Equivalents at End of Year

1,168,673,821


675,466,608 

Net Operating Cash Flows Per Share

11.69

 

13.50

 

* Includes Cash and Cash Equivalents of Synovia Pharma PLC at the date of acquisition. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR UPGAUGUPPUQR